• 1. An asymmetric supercapacitor based on controllable WO3 nanorod bundle and alfalfa-derived porous carbon?
  Kanjun Sun,Fengting Hua,Shuzhen Cui,Yanrong Zhu,Hui Peng,Guofu Ma RSC Adv., 2021,11, 37631-37642
• 2. An integrated process of CO2 capture and in situ hydrogenation to formate using a tunable ethoxyl-functionalized amidine and Rh/bisphosphine system?
  Yu-Nong Li,Liang-Nian He,Xian-Dong Lang,Xiao-Fang Liu,Shuai Zhang RSC Adv., 2014,4, 49995-50002
• 3. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 4. An Appraisal of pH triggered Bacitracin drug release, through composite hydrogel systems
  RabailGul,MariamMir,MurtazaNAli
• 5. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782

5-Chloro-3-ethyl-1-(2-fluorophenyl)-1H-pyrazole-4-carbaldehyde: A Novel Scaffold for Targeted Therapeutic Applications

5-Chloro-3-ethyl-1-(2-fluorophenyl)-1H-pyrazole-4-carbaldehyde (CAS No. 1152583-51-1) represents a structurally unique compound that has garnered significant attention in recent years due to its potential applications in medicinal chemistry. This molecule belongs to the class of pyrazole derivatives, which are known for their diverse biological activities, including anti-inflammatory, antitumor, and antimicrobial properties. The 5-chloro substituent at the pyrazole ring, combined with the 2-fluorophenyl group at the aromatic ring, creates a complex molecular framework that may contribute to its pharmacological profile. The 3-ethyl group and the carbaldehyde functionality further enhance its reactivity and potential for chemical modification, making it a promising candidate for drug development.

Recent studies have highlighted the importance of pyrazole-4-carbaldehyde scaffolds in the design of small molecule inhibitors targeting specific enzymatic pathways. For instance, a 2023 publication in Journal of Medicinal Chemistry demonstrated that compounds with similar structural features exhibit potent inhibitory activity against kinases involved in cancer progression. The 2-fluorophenyl substituent has been shown to modulate the electronic properties of the aromatic ring, which may enhance the compound's ability to interact with biological targets such as protein kinases or G-protein coupled receptors (GPCRs). These interactions are critical for the development of drugs targeting diseases with complex pathophysiology, such as neurodegenerative disorders and autoimmune conditions.

One of the key advantages of 5-Chloro-3-ethyl-1-(2-fluorophenyl)-1H-pyrazole-4-carbaldehyde is its potential for scaffold-based drug design. The carbaldehyde group at the pyrazole ring can participate in various types of chemical reactions, including Michael addition and nucleophilic substitution, which allows for the creation of diverse derivatives with tailored biological activities. This property is particularly valuable in the context of combinatorial chemistry, where the goal is to generate a library of compounds with varying functional groups to optimize drug efficacy and reduce side effects. The 5-chloro substituent may also contribute to the molecule's metabolic stability, as halogenated groups are often resistant to enzymatic degradation in vivo.

Emerging research in the field of medicinal chemistry has focused on the role of pyrazole derivatives in modulating signaling pathways associated with chronic inflammation. A 2023 study published in Pharmaceutical Research reported that compounds with similar structural motifs to 5-Chloro-3-ethyl-1-(2-fluorophenyl)-1H-pyrazole-4-carbaldehyde exhibit anti-inflammatory effects by inhibiting the NF-κB pathway, which is a key regulator of immune responses. The 2-fluorophenyl group may play a critical role in this mechanism by interacting with specific residues in the target protein, thereby disrupting signal transduction. This finding underscores the potential of this compound as a lead molecule for the development of anti-inflammatory drugs.

Another area of interest is the application of 5-Chloro-3-ethyl-1-(2-fluorophenyl)-1H-pyrazole-4-carbaldehyde in the treatment of neurodegenerative diseases. Recent studies have suggested that pyrazole-based compounds may have neuroprotective properties by modulating the activity of enzymes involved in oxidative stress. A 2023 review in Neuropharmacology highlighted the potential of such scaffolds in targeting the accumulation of toxic protein aggregates, which are characteristic of conditions like Alzheimer's disease and Parkinson's disease. The carbaldehyde functionality may contribute to this effect by forming reversible interactions with protein targets, potentially preventing the formation of harmful aggregates.

From a synthetic perspective, the preparation of 5-Chloro-3-ethyl-1-(2-fluorophenyl)-1H-pyrazole-4-carbaldehyde involves a series of well-established chemical reactions. The synthesis typically begins with the condensation of a suitable aromatic amine and a ketone, followed by the introduction of the 2-fluorophenyl group through a coupling reaction. The 5-chloro substituent is often introduced via a halogenation step, which requires careful control of reaction conditions to ensure selectivity. The 3-ethyl group can be added through alkylation reactions, where the molecule serves as a nucleophile in the presence of an electrophilic reagent. These synthetic strategies highlight the versatility of the compound and its potential for further modification to enhance its therapeutic properties.

The pharmacokinetic profile of 5-Chloro-3-ethyl-1-(2-fluorophenyl)-1H-pyrazole-4-carbaldehyde is an important consideration for its development as a pharmaceutical agent. The carbaldehyde group may influence the compound's solubility and bioavailability, which are critical factors in drug design. Studies have shown that the introduction of polar functional groups, such as the carbaldehyde moiety, can improve the water solubility of small molecules, thereby enhancing their absorption in the gastrointestinal tract. However, the presence of halogenated groups, such as the 5-chloro substituent, may also affect the compound's metabolic stability, as these groups are often resistant to enzymatic breakdown. This dual effect highlights the need for further investigation into the compound's pharmacokinetic behavior in vivo.

In conclusion, 5-Chloro-3-ethyl-1-(2-fluorophenyl)-1H-pyrazole-4-carbaldehyde represents a promising scaffold for the development of novel therapeutics. Its unique structural features, including the 5-chloro, 2-fluorophenyl, 3-ethyl, and carbaldehyde groups, offer opportunities for targeted drug design and the modulation of specific biological pathways. Ongoing research in medicinal chemistry and pharmacology is likely to uncover new applications for this compound, further expanding its potential in the treatment of complex diseases.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)